Literature DB >> 25113764

Frontiers in radiotherapy for early-stage invasive breast cancer.

Christine M Fisher1, Rachel Rabinovitch2.   

Abstract

The development of breast-conserving treatment for early-stage breast cancer is one of the most important success stories in radiation oncology in the latter half of the twentieth century. Lumpectomy followed by radiotherapy provides an appealing alternative to mastectomy for many women. In recent years, there has been a shift in clinical investigational focus toward refinements in the methods of delivering adjuvant radiotherapy that provide shorter, more convenient schedules of external-beam radiotherapy and interstitial treatment. Expedited courses of whole-breast treatment have been demonstrated to be equivalent to traditional lengthier courses in terms of tumor control and cosmetic outcome and to provide an opportunity for cost efficiencies.
© 2014 by American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  2014        PMID: 25113764      PMCID: PMC4152718          DOI: 10.1200/JCO.2014.55.1184

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  41 in total

1.  Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy.

Authors:  Ivo A Olivotto; Timothy J Whelan; Sameer Parpia; Do-Hoon Kim; Tanya Berrang; Pauline T Truong; Iwa Kong; Brandy Cochrane; Alan Nichol; Isabelle Roy; Isabelle Germain; Mohamed Akra; Melanie Reed; Anthony Fyles; Theresa Trotter; Francisco Perera; Wayne Beckham; Mark N Levine; Jim A Julian
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

2.  Early-stage breast cancer treated with 3-week accelerated whole-breast radiation therapy and concomitant boost.

Authors:  Manjeet Chadha; Rudolph Woode; Jussi Sillanpaa; David Lucido; Susan K Boolbol; Laurie Kirstein; Michael P Osborne; Sheldon Feldman; Louis B Harrison
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-01-04       Impact factor: 7.038

3.  Intraoperative electron beam radiotherapy (ELIOT) to the breast: a need for a quality assurance programme.

Authors:  R Orecchia; M Ciocca; G Tosi; S Franzetti; A Luini; G Gatti; U Veronesi
Journal:  Breast       Date:  2005-10-19       Impact factor: 4.380

4.  Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial.

Authors:  John Yarnold; Anita Ashton; Judith Bliss; Janis Homewood; Caroline Harper; Jane Hanson; Jo Haviland; Søren Bentzen; Roger Owen
Journal:  Radiother Oncol       Date:  2005-03-16       Impact factor: 6.280

Review 5.  Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline.

Authors:  Benjamin D Smith; Soren M Bentzen; Candace R Correa; Carol A Hahn; Patricia H Hardenbergh; Geoffrey S Ibbott; Beryl McCormick; Julie R McQueen; Lori J Pierce; Simon N Powell; Abram Recht; Alphonse G Taghian; Frank A Vicini; Julia R White; Bruce G Haffty
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-16       Impact factor: 7.038

6.  Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer.

Authors:  J A Jacobson; D N Danforth; K H Cowan; T d'Angelo; S M Steinberg; L Pierce; M E Lippman; A S Lichter; E Glatstein; P Okunieff
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

7.  Three-year outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost.

Authors:  Mark W McDonald; Karen D Godette; Daisy J Whitaker; Lawrence W Davis; Peter A S Johnstone
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-09-21       Impact factor: 7.038

8.  Radiation therapy as primary treatment for early stage carcinoma of the breast.

Authors:  L R Prosnitz; I S Goldenberg
Journal:  Cancer       Date:  1975-06       Impact factor: 6.860

9.  Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer.

Authors:  D Sarrazin; M G Lê; R Arriagada; G Contesso; F Fontaine; M Spielmann; F Rochard; T Le Chevalier; J Lacour
Journal:  Radiother Oncol       Date:  1989-03       Impact factor: 6.280

10.  The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.

Authors:  Joanne S Haviland; J Roger Owen; John A Dewar; Rajiv K Agrawal; Jane Barrett; Peter J Barrett-Lee; H Jane Dobbs; Penelope Hopwood; Pat A Lawton; Brian J Magee; Judith Mills; Sandra Simmons; Mark A Sydenham; Karen Venables; Judith M Bliss; John R Yarnold
Journal:  Lancet Oncol       Date:  2013-09-19       Impact factor: 41.316

View more
  9 in total

1.  Targeting RLIP with CRISPR/Cas9 controls tumor growth.

Authors:  Jyotsana Singhal; Shireen Chikara; David Horne; Sanjay Awasthi; Ravi Salgia; Sharad S Singhal
Journal:  Carcinogenesis       Date:  2021-02-11       Impact factor: 4.944

Review 2.  Emerging Role of Hypofractionated Radiotherapy with Simultaneous Integrated Boost in Modern Radiotherapy of Breast Cancer.

Authors:  Mirko Nitsche; Juergen Dunst; Ulrich M Carl; Robert M Hermann
Journal:  Breast Care (Basel)       Date:  2015-07-10       Impact factor: 2.860

Review 3.  Hypofractionated whole breast irradiation: new standard in early breast cancer after breast-conserving surgery.

Authors:  Kyung Su Kim; Kyung Hwan Shin; Noorie Choi; Sea-Won Lee
Journal:  Radiat Oncol J       Date:  2016-06-17

4.  A Comparative Study of Daily 3-Gy Hypofractionated and 1.8-Gy Conventional Breast Irradiation in Early-Stage Breast Cancer.

Authors:  Sea-Won Lee; Yeon-Joo Kim; Kyung Hwan Shin; Kyubo Kim; Eui Kyu Chie; Wonshik Han; Seock-Ah Im; So-Youn Jung; Keun Seok Lee; Eun Sook Lee
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

Review 5.  Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era.

Authors:  David Azria; Ariane Lapierre; Sophie Gourgou; Dirk De Ruysscher; Jacques Colinge; Philippe Lambin; Muriel Brengues; Tim Ward; Søren M Bentzen; Hubert Thierens; Tiziana Rancati; Christopher J Talbot; Ana Vega; Sarah L Kerns; Christian Nicolaj Andreassen; Jenny Chang-Claude; Catharine M L West; Corey M Gill; Barry S Rosenstein
Journal:  Front Oncol       Date:  2017-04-27       Impact factor: 6.244

6.  Can the Adoption of Hypofractionation Guidelines Expand Global Radiotherapy Access? An Analysis for Breast and Prostate Radiotherapy.

Authors:  Omoruyi Credit Irabor; William Swanson; Fiza Shaukat; Johanna Wirtz; Abba Aji Mallum; Twalib Ngoma; Ahmed Elzawawy; Paul Nguyen; Luca Incrocci; Wilfred Ngwa
Journal:  JCO Glob Oncol       Date:  2020-04

7.  Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis.

Authors:  Jian Gao; Shuang Peng; Xinni Shan; Guoliang Deng; Lihong Shen; Jian Sun; Chunhong Jiang; Xiaoling Yang; Zhigang Chang; Xinchen Sun; Fude Feng; Lingdong Kong; Yanhong Gu; Wenjie Guo; Qiang Xu; Yang Sun
Journal:  Cell Death Dis       Date:  2019-12-20       Impact factor: 8.469

8.  Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells.

Authors:  Demet Candas-Green; Bowen Xie; Jie Huang; Ming Fan; Aijun Wang; Cheikh Menaa; Yanhong Zhang; Lu Zhang; Di Jing; Soheila Azghadi; Weibing Zhou; Lin Liu; Nian Jiang; Tao Li; Tianyi Gao; Colleen Sweeney; Rulong Shen; Tzu-Yin Lin; Chong-Xian Pan; Omer M Ozpiskin; Gayle Woloschak; David J Grdina; Andrew T Vaughan; Ji Ming Wang; Shuli Xia; Arta M Monjazeb; William J Murphy; Lun-Quan Sun; Hong-Wu Chen; Kit S Lam; Ralph R Weichselbaum; Jian Jian Li
Journal:  Nat Commun       Date:  2020-09-14       Impact factor: 14.919

Review 9.  Breast radiotherapy in elderly women: myths, controversies, and current techniques in the adjuvant setting.

Authors:  Ana Aurora Díaz Gavela; Blanca Vaquero Barrón; Elia Del Cerro Peñalver; Felipe Couñago
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.